Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission ...

Adolescents with SCD often struggle with maintaining friendships, school performance, and participation in extracurricular ...

For the first time, scientists have systematically analyzed somatic mutations in stomach lining tissue to unpick mutational ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

the researchers hope to expand and recruit more patients as part of Phase 2A study. This novel therapeutic approach for treating Parkinson's disease incorporates the use of stem cells derived from ...

Innovent and HUTCHMED received conditional approval for the combo in endometrial cancer from China’s NMPA last year.

There is a trial of strength at the cellular level. Cells are in constant competition with each other and so eliminate ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

Thanks to the scientific efforts of a team led by Professor Suzannah Williams of Oxford University, researchers are looking ...

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

New study demonstrates how high-affinity B cells "bank" their best traits instead of rolling the dice and risking deleterious mutations, with implications for better vaccine design.